Regulatory best practices for global access to medicines, including TB medicines

The U.S. Food and Drug Administration (FDA) Center for Drug Evaluation and Research (CDER) will conduct a three half-days conference Regulatory Best Practices for Global Access to Medicines, Including Anti-TB Medicines on 16-18 August 2022.

The event is intended to help National Medicines Regulatory Authorities (NMRAs) in low- and middle-income countries (LMICs) gain a better understanding of: FDA's role in international regulatory harmonization; how FDA interacts with the World Health Organization and NMRAs to support the process for approving drugs in LMICs; the United States Pharmacopeia (USP) and the U.S. Agency for International Development (USAID) Promoting the Quality of Medicines Plus (PQM+) program’s role in supporting the strengthening of regulatory systems in LMICs, and regulatory resources available to NMRAs in LMICs.

The agenda can be accessed here.

For further details about the event and to register, click here.

To subscribe to the Weekly Newsletter of new posts, enter your email here:


By CDER

Published: Aug. 3, 2022, 2:04 p.m.

Last updated: Aug. 4, 2022, 2:09 p.m.

Tags: Medicines, Access

Print Share